Answers are grounded in this paper and cite their sources.
A series of 18 2-aryl/heteroaryl-4-oxo-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile derivatives (4a–4r) was synthesized by a one-pot, three-component microwaveassisted reaction in methanol at 160 °C for 5 min. Isolated yields ranged from 73% to 90% (mean, 82.9%). The compounds were characterized using known spectroscopic techniques and evaluated further for antioxidant and antimicrobial activities, molecular docking, and computational pharmacokinetic properties. DPPH radical scavenging assays revealed notable antioxidant activity, with compound 4m exhibiting the highest potency (IC 50 = 9.99 µg/mL), followed by 4g (15.07 µg/mL) and 4h (20.14 µg/mL). Antimicrobial testing showed selective inhibition of Escherichia coli, with zones of inhibition of 0-26 mm; compound 4m was the most active (26 mm), approaching streptomycin (27 mm). No inhibition was observed against Bacillus subtilis or Candida albicans. Docking against DNA topoisomerase (PDB ID: 3FV5) gave scores of -6.2 to -7.4 kcal/mol, with 4m scoring best (-7.4 kcal/mol). In a 100 ns molecular-dynamics simulation, the 4m complex had an average RMSD of 1.16 Å, and MMGBSA estimated a binding free energy of -67.26 ± 3.07 kcal/mol. SwissADME predictions indicated zero Lipinski violations and high gastrointestinal absorption; predicted CYP inhibition and other alerts require further assessment. These findings identify 4m as an experimental lead for follow-up studies, while computational predictions require biological validation.
No takes yet. Share an insight, caveat, or question.
Jadhav et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: